{"id":"NCT03732638","sponsor":"Pfizer","briefTitle":"Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults","officialTitle":"A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-11-14","primaryCompletion":"2019-12-10","completion":"2021-02-02","firstPosted":"2018-11-06","resultsPosted":"2021-08-09","lastUpdate":"2024-06-07"},"enrollment":1590,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Rimegepant","otherNames":["BHV-3000"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"DBT Rimegepant/OL Rimegepant","type":"EXPERIMENTAL"},{"label":"DBT Placebo/OL Rimegepant","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.","primaryOutcome":{"measure":"Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase","timeFrame":"OP and Weeks 9 to 12 of the DBT phase","effectByArm":[{"arm":"Rimegepant - Randomization Phase","deltaMin":-4.3,"sd":null},{"arm":"Placebo - Randomization Phase","deltaMin":-3.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0099"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":93,"countries":["United States"]},"refs":{"pmids":["40583813","38174577","36417057","33338437"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":370},"commonTop":["Upper respiratory tract infection","Nasopharyngitis"]}}